HER2-Negative Breast Cancer Not Yet Recruiting Phase 3 Trials for Capecitabine (DB01101)

IndicationStatusPhase
DBCOND0072181 (HER2-Negative Breast Cancer)Not Yet Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03613181ANG1005 in Leptomeningeal Disease From Breast CancerTreatment